Sistemic Ltd is a UK-based product development company focusing on leveraging the instructive power of microRNA (miRNA) to provide cutting-edge products for the Bioprocessing, Cell (and Stem Cell) Therapy, and Drug Discovery and Development markets. The company offers a wide range of products, including robust quality control (QC) for cells and toxicity and drug response-based products for Pharmaceutical markets. These innovative products enable companies worldwide to deliver drugs and therapies successfully and in a cost-effective manner, providing valuable data on a range of cell systems.
At the core of Sistemic's pioneering products lies their IP and core expertise within robust miRNA profiling, superior statistical analytics, and multi-layered contextual analysis, collectively known as the Sistemic Methodology. By harnessing the instructive power of miRNA, Sistemic provides a systems approach that yields data indicative of biology and informative of actual effect, offering a rigorous yet rapid understanding of the biological changes within a cell. This empowers companies to make well-informed decisions and develop their cell (or stem cell) therapies and drug development pipelines more successfully and cost-effectively.
Founded in 2009, Sistemic operates in the Biotechnology, Health Care, and Pharmaceutical industries. The company received a $1.00M Series A investment from ChimeraBio on 17th March 2010. With its groundbreaking approach to product development and its focus on leveraging miRNA for impactful solutions, Sistemic is poised to make significant contributions in the biotechnology and pharmaceutical sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $1.00M | 1 | ChimeraBio | 17 Mar 2010 |
No recent news or press coverage available for Sistemic Ltd.
We care about your data, and we'd love to use cookies make your experience better.
